CXCR4 and breast carcinoma: In the current study, we discussed whether platelet-derived growth factor receptor-α (PDGFRα) is required for SDF-1α/CXCR4 signaling and explored how NT21MP contributes to reversing CXCR4-induced EMT to provide insight into the potential efficacy of NT21MP as adjuvant chemotherapy for breast cancer.